BGI Group
Chinese genome sequencing company / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about BGI Group?
Summarize this article for a 10 year old
BGI Group, formerly Beijing Genomics Institute, is a Chinese genomics company with headquarters in Yantian, Shenzhen. The company was originally formed in 1999 as a genetics research center to participate in the Human Genome Project.[3][4] It also sequences the genomes of other animals, plants and microorganisms.[5]
Native name | 華大集團 |
---|---|
Formerly | Beijing Genomics Institute |
Company type | Private |
Industry | Omics Genome sequencing Biotechnology |
Founded | September 9, 1999; 24 years ago (1999-09-09) |
Founder | Wang Jian Yu Jun Yang Huanming Liu Siqi |
Headquarters | Shenzhen, Guangdong, China |
Number of locations | A global presence in more than 100 countries and regions[1][2] |
Area served | Worldwide |
Key people | Wang Jian (Co-Founder and Chairman) |
Products | DNBseq Platform (next-generation sequencing platform), RT-PCR tests for the detection of the SARS CoV-2 virus and its mutations. Huo-Yan integrated laboratory solution. The NIFTY Test (a non-invasive prenatal test) |
Brands | DNBseq, NIFTY, Huafeiran, Huachangkang, Huajianwei, Huachangan, Huafanan, SeqHPV, PMseq |
Revenue | $251 million (2016)[2] |
$51.7 million (2016)[2] | |
Owner | Wang Jian |
Number of employees | ~ 10,000 (worldwide) |
Divisions | BGI China (Mainland) BGI Asia Pacific BGI Americas BGI Europe (Europe and Africa) |
Subsidiaries |
|
Website | genomics |
BGI has transformed from a small research institute, notable for decoding the DNA of pandas and rice plants, into a diversified company active in animal cloning, health testing, and contract research.[6][7][8] BGI's earlier research was continued by the Beijing Institute of Genomics, Chinese Academy of Sciences.[9] BGI Research, the group's nonprofit division, works with the Institute of Genomics and operates the China National GeneBank under a contract with the Chinese government.[10][11] BGI Genomics, a subsidiary, was listed on the Shenzhen Stock Exchange in 2017.
Starting in 2021, details came to light about multiple controversies involving the BGI Group.[12] These controversies include alleged collaboration with the People's Liberation Army (PLA) and use of genetic data from prenatal tests.[13] BGI denied that it shares prenatal genetics data with the PLA.[14]